Cell and Gene Therapy Bioprocessing Market Size, Share & Forecast 2025–2035
What Is the Cell and Gene Therapy Bioprocessing Market Size?
The global Cell and Gene Therapy Bioprocessing market was valued at USD 5.2 Billion in 2025 and is projected to grow from USD 6.1 Billion in 2026 to USD 24.7 Billion by 2035, at a CAGR of 16.8% from 2026–2035.
Cell and Gene Therapy Bioprocessing Market Key Takeaways
According to Next Move Strategy Consulting analysis, brand owners and enterprise buyers are increasingly consolidating vendor sourcing with fewer, certification-ready suppliers to simplify multi-region regulatory compliance, a shift that favors diversified manufacturers over single-region specialists as regulatory scrutiny intensifies through 2035.
What Does the Cell and Gene Therapy Bioprocessing Market Encompass?
The market covers the equipment, consumables, analytics, media, and outsourced services used to manufacture cell and gene therapy products, including autologous and allogeneic cell products, viral vectors, plasmid DNA, and emerging in vivo editing platforms. Its structural evolution has shifted from academic, hospital-scale production toward closed, automated, GMP-compliant platforms supplied by specialized vendors and contract manufacturers, shaped by regulatory frameworks such as the FDA's CBER pathways and the EMA's ATMP framework.
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 5.2 Billion |
| Market Size in 2026 | USD 6.1 Billion |
| Revenue Forecast in 2035 | USD 24.7 Billion |
| Growth Rate | CAGR of 16.8% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 35+ Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the Cell and Gene Therapy Bioprocessing Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Cell and Gene Therapy Bioprocessing industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the Cell and Gene Therapy Bioprocessing market through 2035, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Expanding CAR-T and ex vivo cell therapy pipelines | GROWTH DRIVER | High | Sustains the largest application demand base at USD 2.44 Billion in 2025 | 2026–2030 |
| Shift toward closed, single-use manufacturing | GROWTH DRIVER | High | Drives demand for consumables and biopreservation media | 2026–2035 |
| Government-supported cell therapy programs in Asia-Pacific | GROWTH DRIVER | Medium | Accelerates regional capacity build-out at 20.2% CAGR | 2026–2035 |
| High cost of GMP facility construction and validation | RESTRAINT | High | Limits new entrant capacity and extends commercialization timelines | 2026–2030 |
| Shortage of skilled bioprocess talent in emerging regions | RESTRAINT | Medium | Constrains faster growth in Latin America and Middle East & Africa | 2026–2033 |
| Complex and variable regulatory pathways across regions | RESTRAINT | Medium | Lengthens product approval and manufacturing scale-up cycles | 2026–2035 |
How Do Mandated Quality Standards Anchor Baseline Demand?
Regulatory requirements for GMP compliance and validated sterility establish a demand anchor, or compliance floor, that sustains consumable and testing purchases irrespective of growth cycles. This baseline supports the single-use consumables category, which holds the largest offering share, but it should be distinguished from the genuine growth engine represented by high-CAGR emerging applications.
Which Emerging Applications Serve as the Growth Vector?
We observed that in vivo gene editing and mRNA-enabled reprogramming is the primary growth vector, with a 25.6% CAGR over 2026–2035, substantially above the 13.0% CAGR of autologous CAR-T manufacturing. High-CAGR emerging segments thus carry the market's expansion, while mature autologous production provides a stable but slower-growing base.
What Restrains Adoption in Emerging Regions?
Our findings suggest that limited domestic GMP infrastructure and talent depth constrain faster expansion in Latin America and parts of the Middle East and Africa. Brazil and Argentina are expanding clinical trial activity, yet these constraints moderate their pace relative to Asia-Pacific, which records a 20.2% CAGR over 2026–2035.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the Single-Use Bioreactors, Closed-System Consumables & Biopreservation Media segment held the dominant market share in 2025. Meanwhile, the Process Analytics, Automation Platforms & Digital Bioprocess Software segment is anticipated to be the fastest-growing, expanding at a CAGR of 19.9% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Single-Use Bioreactors, Closed-System Consumables & Biopreservation Media | 2.70 | 3.12 | 10.87 | 14.9% |
| Process Analytics, Automation Platforms & Digital Bioprocess Software | 1.61 | 1.95 | 10.00 | 19.9% |
| Contract Development, Manufacturing & Quality Testing Services | 0.89 | 1.03 | 3.83 | 15.7% |
| Total | 5.2 | 6.1 | 24.7 | 16.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Autologous CAR-T and Ex Vivo Cell Therapy Manufacturing segment held the dominant market share in 2025. Meanwhile, the In Vivo Gene Editing and mRNA-Enabled Cell Reprogramming Platforms segment is anticipated to be the fastest-growing, expanding at a CAGR of 25.6% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Autologous CAR-T and Ex Vivo Cell Therapy Manufacturing | 2.44 | 2.79 | 8.40 | 13.0% |
| Viral Vector and Plasmid DNA Production for Gene Therapy | 1.61 | 1.90 | 8.15 | 17.6% |
| Allogeneic Stem Cell and Mesenchymal Stromal Cell Bioprocessing | 0.73 | 0.87 | 3.95 | 18.3% |
| In Vivo Gene Editing and mRNA-Enabled Cell Reprogramming Platforms | 0.42 | 0.54 | 4.20 | 25.6% |
| Total | 5.2 | 6.1 | 24.7 | 16.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Commercial Biopharma Sponsors and Drug Developers segment held the dominant market share in 2025. Meanwhile, the Contract Development & Manufacturing Organizations (CDMOs/CGMOs) segment is anticipated to be the fastest-growing, expanding at a CAGR of 21.7% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Commercial Biopharma Sponsors and Drug Developers | 3.02 | 3.52 | 11.32 | 13.9% |
| Contract Development & Manufacturing Organizations (CDMOs/CGMOs) | 1.51 | 1.93 | 11.32 | 21.7% |
| Academic Medical Centers, Hospitals & Non-Profit Research Institutes | 0.67 | 0.65 | 2.06 | 13.7% |
| Total | 5.2 | 6.1 | 24.7 | 16.8% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Where Can Vendors Capture Outsourced Capacity Demand?
Our assessment indicates that CDMOs and CGMOs present a whitespace opportunity, with their value expanding at a 24.2% CAGR over 2026–2035. Vendors offering validated, closed-system platforms and turnkey GMP support can align with this outsourcing trend.
How Can Suppliers Address Biopreservation Supply Gaps?
We observed that the integration of biopreservation media with cell therapy workflows is gaining strategic relevance. Consolidation within the supply chain, exemplified by Repligen's acquisition of BioLife Solutions, signals demand for integrated consumable portfolios covering media and processing hardware.
Which Emerging Regions Offer Early-Stage Entry Points?
Based on research conducted by our analysts, we found that Latin America and Middle East & Africa offer early-stage entry points, with CAGRs of 19.0% and 15.9% respectively over 2026–2035. Partnerships addressing talent development and local GMP infrastructure could unlock these regional pools.
Investment Opportunities
Capital Inflows
Capital is increasingly directed toward closed-system platform suppliers and CDMO capacity, reflecting the 16.8% overall CAGR (2026–2035). Investors are prioritizing assets that combine validated GMP operations with scalable automation, supporting durable returns across the value chain.
Infrastructure
Investment in GMP-compliant facilities and automated process lines is central to meeting outsourcing demand, particularly the 24.2% CAGR of CDMOs and CGMOs. Regional infrastructure build-out in Asia-Pacific, at a 20.2% CAGR, offers additional greenfield opportunities.
ESG
Single-use systems reduce water and cleaning-validation burdens relative to stainless steel, aligning manufacturing with sustainability objectives. Partnerships that build local talent and clinical infrastructure in emerging regions also strengthen the social dimension of investment strategies.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Cell and Gene Therapy Bioprocessing heading into 2035.
Established concentration of CGT developers, FDA-approved launches, and mature contract manufacturing clusters in North America provide a strong demand foundation. Closed-system consumable platforms have reached commercial maturity, supporting predictable recurring revenue for suppliers.
High capital intensity of GMP facilities and specialized validation requirements raise barriers for smaller developers. Talent shortages in several regions limit how quickly new capacity can be commissioned and operated.
In vivo gene editing and mRNA-enabled platforms at a 15.4% CAGR open a high-growth application pool. Expanding CDMO outsourcing at 24.2% CAGR creates demand for scalable, validated manufacturing partners.
Regulatory divergence across jurisdictions can extend approval timelines and complicate multi-region manufacturing. Evolving manufacturing technologies could shift demand away from current platform formats, creating obsolescence risk for certain equipment investments.
Access the Full Market Report
35+ Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 2.41 Billion in 2025 and estimated at USD 2.8 Billion in 2026, reaching USD 10.13 Billion by 2035 at a 15.4% CAGR (2026–2035). The region benefits from dense developer concentration and established clusters in Boston, San Francisco, and North Carolina. Its share is gradually moderating as Asia-Pacific scales, though it retains leadership.
United States
CanadaEurope was valued at USD 1.46 Billion in 2025 and estimated at USD 1.7 Billion in 2026, reaching USD 6.55 Billion by 2035 at a 16.2% CAGR (2026–2035). Academic-industrial hubs in the UK, Germany, and France, supported by the EMA's ATMP framework, sustain steady demand. Hospital-based manufacturing initiatives add a complementary channel for clinical-scale production.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 1.01 Billion in 2025 and estimated at USD 1.23 Billion in 2026, reaching USD 6.42 Billion by 2035 at a 20.2% CAGR (2026–2035). Government-supported cell therapy programs and lower-cost manufacturing underpin rapid build-out across China, Japan, South Korea, and Singapore. This region posts the fastest regional expansion in the forecast.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 0.17 Billion in 2025 and estimated at USD 0.2 Billion in 2026, reaching USD 0.96 Billion by 2035 at a 19.0% CAGR (2026–2035). Brazil and Argentina are expanding clinical trial activity and regional biomanufacturing partnerships. Limited domestic GMP infrastructure moderates the pace of expansion.
Brazil
ArgentinaMiddle East & Africa was valued at USD 0.15 Billion in 2025 and estimated at USD 0.17 Billion in 2026, reaching USD 0.64 Billion by 2035 at a 15.9% CAGR (2026–2035). Gulf states including the UAE and Saudi Arabia are investing in advanced therapy hubs and sovereign biomanufacturing ambitions. This region is the smallest region in the snapshot, with limited talent depth across the wider territory tempering growth.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
We observed that the sector is consolidating around integrated consumable and media portfolios. Repligen's transaction signals a strategic move to combine processing hardware with cell therapy biopreservation capabilities.
Cell and Gene Therapy Bioprocessing Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Moderately fragmented, with specialized equipment vendors, consumable suppliers, and CDMOs coexisting |
| Innovation Focus | Closed-system automation, digital process analytics, and integrated biopreservation media |
| M&A Activity | Active consolidation, including Repligen's acquisition of BioLife Solutions in 2026 |
Source: Healthcare Industry Insights Analysis, 2026
Vendor Consolidation Dynamics
We observed that the sector is consolidating around integrated consumable and media portfolios. Repligen's transaction signals a strategic move to combine processing hardware with cell therapy biopreservation capabilities.
Automation and Digital Platform Competition
Our findings suggest that vendors are competing on digital process control and closed-system automation. The process analytics segment's 19.9% CAGR (2026–2035) rewards suppliers that deliver real-time quality monitoring.
CDMO Capacity Positioning
Based on research conducted by our analysts, we found that CDMOs and CGMOs are competing on validated GMP capacity and regional footprint. The 24.2% CAGR of this end-user category (2026–2035) draws new entrants and expansions.
Talent and Partnership Strategies
Healthcare Industry Insights's analysis indicates that academic and workforce partnerships, such as Made Scientific's collaboration with NJIT and ISCT workforce programs, are becoming a competitive lever for securing skilled operators.
Key Market Players in the Cell and Gene Therapy Bioprocessing
Key companies active in the global Cell and Gene Therapy Bioprocessing include:
Latest Cell and Gene Therapy Bioprocessing Industry Developments
We found that recent product launches within the Cell and Gene Therapy Bioprocessing are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| October 2026 | Repligen completed its acquisition of BioLife Solutions, adding biopreservation media to its cell therapy capabilities. | Official Press Release |
| July 2026 | Repligen announced plans to acquire BioLife Solutions to expand its cell therapy biopreservation media offerings. | Official Press Release |
| April 1, 2026 | University College London: UCL short course on cell and gene therapy bioprocessing with Bioprocess Industries MBI training is listed for enrollment. | Official Announcement |
| February 1, 2026 | ISCT published its workforce development programming for cell and gene therapy professionals. | Official Announcement |
| November 2025 | PBS Biotech appointed Martin Simonetti as Chief Executive Officer effective October 27, 2025. | Official Press Release |
| January 2025 | Made Scientific and NJIT partnered to enhance cell and gene therapy bioprocessing curriculum. | Official Announcement |
| January 2025 | Made Scientific and Sentinel BioTherapeutics announced a strategic manufacturing partnership for an allogeneic encapsulated cell therapy program. | Official Announcement |
| January 2025 | Nucleus Biologics valuation and funding history is documented in a public company profile. | Official Announcement |
Source: Healthcare Industry Insights Analysis, 2026
Expert Insights: Cell and Gene Therapy Bioprocessing
Through our market assessment, we gathered perspectives from senior executives active in the cell and gene therapy bioprocessing ecosystem.
Market Interpretation
Healthcare Industry Insights's analysis indicates that this statement from Repligen's chief executive signals the operational integration of biopreservation media into a broader cell therapy processing portfolio. Our findings suggest that the acquisition consolidates supply for clinicians and manufacturers who need validated, end-to-end workflows. Based on research conducted by our analysts, we found that such integration can shorten qualification cycles for sponsors and CDMOs scaling commercial batches.
Key Benefits for Cell and Gene Therapy Bioprocessing Stakeholders
Stakeholder
Manufacturers gain from validated closed-system platforms that reduce contamination risk and changeover time. Aligning with the 25.6% CAGR of in vivo and mRNA-enabled platforms helps leadership prioritize capacity planning around the market's fastest-growing application.
Stakeholder
Investors can target the Absolute Dollar Opportunity of USD 18.6 Billion between 2026 and 2035, weighing the growth vector of high-CAGR segments against the stable demand anchor of mature consumable categories. Diversifying across offerings and regions balances risk.
Stakeholder
Vendors providing process analytics and automation software can capture the 19.9% CAGR of the digital offering segment. Integration with closed-system hardware and consumables creates recurring revenue and deepens customer relationships.
Conclusion and Recommendations
Long-Term Outlook
The market is projected to expand from USD 6.1 Billion in 2026 to USD 24.7 Billion by 2035 at a 16.8% CAGR (2026–2035). Sustained adoption of closed, automated manufacturing underpins this trajectory across regions.
Strategic Positioning Recommendations
Suppliers should build integrated portfolios spanning consumables, media, and digital controls. Aligning product roadmaps with the 19.9% CAGR of process analytics strengthens competitive positioning.
Investment Attractiveness
Closed-system platforms and CDMO capacity offer attractive risk-adjusted profiles. The Absolute Dollar Opportunity of USD 18.6 Billion between 2026 and 2035 supports sustained capital deployment.
Market Shifts and Key Risks
Regulatory divergence and talent shortages are the principal risks. Manufacturers should monitor approval pathways and invest in workforce development to mitigate execution delays.
Growth Pathways
Primary growth pathways shift toward in vivo gene editing and mRNA-enabled platforms at a 15.4% CAGR, while autologous manufacturing serves as the stable demand anchor. Asia-Pacific's 20.2% CAGR signals regional diversification opportunities.
Frequently Asked Questions
Consolidated Source Table
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.